Program
Anti-SLITRK6 Antibody-drug Conjugate GEN1106
Its studies are mostly in Carcinoma, Transitional Cell, led by Genmab.
Furthest: phase 1, since Feb 10, 20261 company-led study, 1 open or runningNext primary completion: Apr 5, 2029 (phase 1)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Genmab | 11 open or running | phase 1since Feb 10, 2026 | Feb 10, 2026 | Apr 5, 2029phase 1 · NCT07416123 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Feb 10, 2026First study: phase 1 study in Carcinoma, Transitional CellFirst studyNCT07416123 · 103 planned · United States, Japan, Spain
Ahead
- Apr 5, 2029Primary completion: phase 1 study in Carcinoma, Transitional CellNCT07416123
TargetBeta
SLITRK6 →read by rule
“An antibody-drug conjugate (ADC) composed of a monoclonal antibody directed against SLIT and NTRK-like protein 6 (SLITRK6), ”NCIt, by rule
Studies
All 1 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07416123Carcinoma, Transitional Cell · United States, Japan, Spain | 1 | Recruiting | Apr 5, 2029 | 103 |
How it is read
Names in the registry
- “GEN1106”, 1 entry
Conditions, from the studies’ own filings
- Carcinoma, Transitional Cell, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.